Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Patient-centricity

- PMLiVE

Building and delivering market access capabilities in emerging markets

Local skills gaps must be addressed if the potential of the BRIC countries is to be realised

- PMLiVE

Modern values in healthcare

Understanding the new concepts and processes of value will be the first steps towards adapting to a new healthcare environment

- PMLiVE

Interview: David Haslam, NICE

The new chair of the UK’s NICE discusses navigating the stormy waters of health service reforms, collaborating with pharma and the introduction of VBP

China flag thumb

Pharma nervous as China probes drug prices

Local affiliates of multinationals and domestic companies in the spot light

EU flag

The future of HTA harmonisation in Europe

The variety and variability of European health technology assessment criteria have created a challenging environment for pharma and a need for much greater harmonisation

- PMLiVE

Alcon wins initial NICE backing for Jetrea in rare eye condition

Would be first alternative to surgery available to vitreomacular traction patients in England and Wales

- PMLiVE

New healthcare comms agency launches in London

Paradigm Communications will be managed by Porter Novelli

- PMLiVE

Interview: Kay Drake and Naoki Okamura, Astellas

Astellas’ vice president of marketing, Europe and its chief strategy officer, Europe discuss category leadership, the changing landscape of market access and growth in a time of austerity

- PMLiVE

Novo Nordisk: Strict US regulation threatens innovation

Warning from CEO Sorensen comes after Tresiba and Ryzodeg fail to win FDA approval

- PMLiVE

The impact of Hollande’s healthcare reforms in France

A tougher environment for pharma, with market access and regulatory challenges

- PMLiVE

Value-based pricing “not in patient interest”

Think-tank 2020health calls for rethink of UK drug pricing plans

- PMLiVE

Roche survey says Scottish cancer patients moving house to get treatment

But NHS Scotland hits back at report's "extremely dubious" findings

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links